Abstract / Description of output
Background: Hypercobalaminemia is infrequently reported in companion animals and considered of low clinical significance. Recent studies have described its association with inflammatory, immune mediated, endocrine and neoplastic conditions in dogs and cats.
Objectives: We aimed to investigate the association between hypercobalaminemia and neoplasia in companion animals, and to identify other concurrent diseases or clinicopathological changes.
Methods: Retrospective, case control study. Medical records of patients with measured serum cobalamin concentration (2015-2020) and no history of prior supplementation were reviewed. Hypocobalaminemic animals were excluded. Variables were compared between groups (hypercobalaminemic vs normocobalaminemic) using non-parametric statistics. Data are presented as median (range).
Results: Thirty-five dogs and 8 cats were hypercobalaminemic. At baseline, neoplasia was confirmed in 4/35 hypercobalaminemic dogs vs. 11/70 control dogs (p=0.77), and 0/8 hypercobalaminemic cats vs. 3/16 control cats (p=0.53). Cases without neoplasia at baseline were followed for 409 (13-1854) days (dogs, n=78) and 395 (28-1670) days (cats, n=21). During follow up, neoplasia was diagnosed in 4/27 hypercobalaminemic dogs vs. 3/51 control dogs (p=0.23), and 1/8 hypercobalaminemic cats vs. 0/13 control cats (p=0.38).
Pancreatitis was more frequent in hypercobalaminemic dogs (p=0.006). Hypercobalaminemic dogs had higher serum total protein (p=0.014), globulin (p=0.001) and CRP (p=0.032) concentrations, and lower serum sodium (p=0.012) and chloride (p=0.033) concentrations than controls. Hypercobalaminemic cats had higher serum total protein concentrations than controls (p=0.008).
Conclusion: Our results suggest that hypercobalaminemia is not associated with presence or development of neoplasia in dogs and cats, but may be associated with systemic inflammatory conditions, including pancreatitis, in dogs.
Objectives: We aimed to investigate the association between hypercobalaminemia and neoplasia in companion animals, and to identify other concurrent diseases or clinicopathological changes.
Methods: Retrospective, case control study. Medical records of patients with measured serum cobalamin concentration (2015-2020) and no history of prior supplementation were reviewed. Hypocobalaminemic animals were excluded. Variables were compared between groups (hypercobalaminemic vs normocobalaminemic) using non-parametric statistics. Data are presented as median (range).
Results: Thirty-five dogs and 8 cats were hypercobalaminemic. At baseline, neoplasia was confirmed in 4/35 hypercobalaminemic dogs vs. 11/70 control dogs (p=0.77), and 0/8 hypercobalaminemic cats vs. 3/16 control cats (p=0.53). Cases without neoplasia at baseline were followed for 409 (13-1854) days (dogs, n=78) and 395 (28-1670) days (cats, n=21). During follow up, neoplasia was diagnosed in 4/27 hypercobalaminemic dogs vs. 3/51 control dogs (p=0.23), and 1/8 hypercobalaminemic cats vs. 0/13 control cats (p=0.38).
Pancreatitis was more frequent in hypercobalaminemic dogs (p=0.006). Hypercobalaminemic dogs had higher serum total protein (p=0.014), globulin (p=0.001) and CRP (p=0.032) concentrations, and lower serum sodium (p=0.012) and chloride (p=0.033) concentrations than controls. Hypercobalaminemic cats had higher serum total protein concentrations than controls (p=0.008).
Conclusion: Our results suggest that hypercobalaminemia is not associated with presence or development of neoplasia in dogs and cats, but may be associated with systemic inflammatory conditions, including pancreatitis, in dogs.
Original language | English |
---|---|
Pages (from-to) | 1-8 |
Number of pages | 8 |
Journal | Veterinary Clinical Pathology: An International Journal of Laboratory Medicine |
Early online date | 12 Jul 2023 |
DOIs | |
Publication status | E-pub ahead of print - 12 Jul 2023 |
Externally published | Yes |
Keywords / Materials (for Non-textual outputs)
- hypercobalaminemia
- cobalamin
- inflammation
- neoplasia
- pancreatitis